PATINA - Clinical trial • Breast Cancer Foundation NZ

PATINA

Advanced Breast Cancer clinical trials for ER+

Recruiting
Updated: November 7, 2019

This study looks at anti-HER2 therapy plus endocrine therapy with or without palbociclib in patients with hormone receptor-positive HER2+ metastatic breast cancer. This study aims to extend the time before the disease progresses.

Subjects will be randomized into one of two treatment arms following a minimum of four and maximum of eight cycles of induction treatment with anti-HER2 therapy.

Arm A subjects will receive the experimental therapy, palbociclib, in addition to their current anti-HER2 therapy and endocrine therapy.

Arm B subjects will continue to receive the anti-HER2 therapy and endocrine therapy.

It is expected that the addition of palbociclib to the first-line treatment of HER2 disease will delay the onset of therapeutic resistance and ultimately prolong the survival of patients with metastatic breast cancer.

The study is designed to treat the subset of patients with HER2+ disease who are also hormone receptor-positive (HR+). It is also expected that palbociclib will modulate the endocrine resistance in HER2+/HR+ disease and potentiate the benefits of anti-HER2 therapy.

Eligibility criteria includes:

  • Minimum 18 years old
  • Confirmed invasive breast cancer that is metastatic or not able to be cured by surgery or radiation therapy
  • Confirmed HER2+ and hormone receptor-positive (ER+ and/or PR+), metastatic breast cancer
  • ECOG performance status 0-1

For full trial information

New Zealand

Auckland City Hospital

Contact:

Emily Allam

Australia

Icon Cancer Care, Brisbane
Mater Cancer Care Centre, Brisbane
The Canberra Hospital, Canberra
Monash Health, Melbourne
Peter MacCallum Cancer Centre, Melbourne
Calvary Mater Newcastle Hospital, Newcastle
St Vincent's Hospital, Sydney
Westmead Hospital, Sydney
Breast Cancer Research Centre, Western Australia

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

  • STARTRK-2 
    Updated: January 17, 2020
    Recruiting
    Australia
    This is an open-label, multicenter, global phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3 or ROS1 gene fusion.
    More details

  • THYmine2
    Updated: May 12, 2020
    Recruiting
    New Zealand
    THYmine2 is an observational study to assess whether the thymine loading test can prospectively categorize patients who cannot tolerate 5-FU treatment (e.g. FOLFOX, CapeOx, FLOX). This treatment is commonly used in breast cancer treatment. Reactions occur in approximately 10% of patients and can result in life-threatening events.
    More details

  • INAVO123
    Updated: January 14, 2020
    Pending
    New Zealand & Australia
    This phase 3 study will evaluate the efficacy and safety of GDC-0077 in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, ER+, HER2-negative locally advanced or metastatic breast cancer.
    More details

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.